Trial · NCT00287287
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
NCT00287287, Phase 2, Completed, Kenneth Ain; results first posted 2020-06-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas. Trials, record NCT00287287. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00287287
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
- NCT number
- NCT00287287
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Kenneth Ain
- Conditions
- Thyroid Neoplasms
- Interventions
- Lenalidomide
- First posted
- 2006-02-06
- Last updated
- 2020-06-12
- Results first posted
- 2020-06-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | 4 years | Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | 4 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Lenalidomide (Revlimid) | 17 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lenalidomide (Revlimid) | 25 | |
| Overall Study | COMPLETED | Lenalidomide (Revlimid) | 25 | |
| Overall Study | NOT COMPLETED | Lenalidomide (Revlimid) | 0 |
Source ClinicalTrials.gov
Adverse events11
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Lenalidomide (Revlimid) | 1 | 25 | |
| other | Fatigue | General disorders | Lenalidomide (Revlimid) | 1 | 25 | |
| other | Weight Loss | General disorders | Lenalidomide (Revlimid) | 1 | 25 | |
| serious | Neutropenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) | 10 | 25 | |
| serious | Leukopenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) | 6 | 25 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) | 4 | 25 | |
| serious | Anemia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) | 1 | 25 | |
| serious | Idiopathic Thrombocytopenic Purpura | Blood and lymphatic system disorders | Lenalidomide (Revlimid) | 1 | 25 | |
| serious | Rash | Social circumstances | Lenalidomide (Revlimid) | 1 | 25 | |
| serious | Pulmonary Embolism | Vascular disorders | Lenalidomide (Revlimid) | 2 | 25 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lenalidomide (Revlimid) | 25 | 25 |
| Total, other adverse events | Lenalidomide (Revlimid) | 3 | 25 |
| Total, serious adverse events | Lenalidomide (Revlimid) | 25 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00287287
GET https://conductscience.org/api/trials/v1/NCT00287287/registered